Lite Strategy, Inc. (LITS)
Nasdaq · Healthcare · Biotechnology
$1.40+1.45%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $42.6M
- 52-week range
- $0.69 – $2.97
- 52-week change
- −43.67%
- EPS (trailing)
- −$2.06
- Next earnings
- Nov 13, 2026
Fiscal year to Jun 2026
- Net income
- −$71.2M
- Diluted EPS
- −$2.06
From the company’s annual report on SEC EDGAR.
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Headquarters: San Diego, United States · 5 employees · litestrategy.com